Abstract
A recent meta-analysis and randomized studies have demonstrated that combined chemoradiotherapy is associated with a survival advantage for selected patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). We conducted a phase II study of combined chemoradiotherapy to find a more effective combination of drugs and radiation than those previously reported for such patients. Between January 1994 and November 1996, 50 previously untreated patients with locally advanced unresectable NSCLC (stage IIIA with N2 or IIIB disease) were entered in this study. Patients were required to have Eastern Cooperative Oncology Group performance status ≤ 2, age ≤ 75 years and adequate organ function. Treatment consisted of three cycles of cisplatin (20 mg m−2, days 1–5) and 5-fluorouracil (5-FU) (500 mg m−2, days 1–5) every 4 weeks, and concurrent hyperfractionated thoracic radiation (1.25 Gy twice daily, with a 6-h interfraction interval; total radiation dose, 62.5–70 Gy). Of the 50 patients entered, 37 (74%) responded to this chemoradiotherapy, including two (4%) with complete response. By a median follow-up time of 41.0 months, 35 patiennts had died and 15 were stil alive. The median time to progression for responding patients was 14.1 months (range, 2.6–51.3+ months). The median survival time was 18.7 months, with a survival rate of 66.0% at 1 year, 46.0% at 2 years and 27.6% at 3 years. Survival outcome was strongly affected by the extent of nodal involvement (median survival time, 27.4 months for N0–2 disease (n = 37) vs 10.7 months for N3 disease (n = 13);P = 0.007). The major toxicities of treatment were leukopenia and neutropenia (≥ Grade 3, 58% and 60% respectively). Other toxicities of ≥ Grade 3 included thrombocytopenia (26%), anaemia (26%), nausea/vomiting (16%) and radiation oesophagitis (6%). Treatment-related death occurred for one patient. Our findings suggest that cisplatin and 5-FU in combination with concurrent hyperfractionated thoracic radiation is effective and feasible for the treatment of locally advanced unresectable NSCLC. The short-term survival in this study appeared to be more encouraging than those of similar chemoradiation trials. A randomized trial will be needed to compare the combination of cisplatin and 5-FU with other platinum-based regimens together with concurrent hyperfractionated thoracic radiation. In addition, in future studies, inclusion criteria for N3 disease with or without supraclavicular involvement should be reconsidered to correctly evaluate the effect of combined chemoradiotherapy for locally advanced unresectable NSCLC. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR and Livingston RB (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13: 1880–1892
Bonner JA, McGinnis WL, Stella PJ, Marschke RF, Sloan JF, Shaw EG, Mailliard JA, Creagan ET, Ahuja RK and Johnson PA (1998) The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma. Cancer 82: 1037–1048
Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M and Einhorn L (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group Protocol. J Clin Oncol 13: 1425–1429
Blanke C, DeVore R, Shyr Y, Epstein B, Murray M, Hande K, Stewart S and Johnson D (1997) A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 17: 111–116
Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T, Grossbard M and Grillo H (1997) Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15: 712–722
Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B and Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16: 3316–3322
Citron ML, Modeas C, Propert K, Goutsou M and Green MR (1992) Phase II trial of high-dose 24-hour continuous intravenous 5-fluorouracil for advanced non-small cell lung cancer. Cancer Invest 10: 215–219
Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J and Green MR (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4–11
Cox JD, Azarnia N, Byhardt RW, Shin KY, Emami B and Pajak TF (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83–11. J Clin Oncol 8: 1543–1555
Dillman RO, Herndon J, Seagren SL, Eaton WL and Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210–1215
Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Müeller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H and Seeber S (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16: 622–634
Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakamura M and Niho Y (1992) Inhibition by 5-fluorouracil of ci s-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 52: 6501–6506
Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S, Matsui K, Masuda N, Takifiji N, Kudoh S, Nishioka M and Fukuoka M (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol 13: 869–875
Furuse K, Fukuoka M, Takada Y, Nishikawa H, Katagami N and Ariyoshi Y (1997) A randomized phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer: preliminary analysis. Proc Am Soc Clin Oncol 16: 459a
Gemma A, Kudoh S, Yoshimura A, Ono Y, Takenaka K, Hayashihara K, Hino M, Shibuya M and Niitani H (1995) Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer. Anticancer Res 15: 2691–2696
Gould C and Sause WT (1995) Radiation therapy for lung cancer. Lung Cancer, Johnson BE, Johnson DH (eds). pp. 191–207. Wiley-Liss: New York
Jeremic B, Shibamoto Y, Acimovic L and Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13: 452–458
Jeremic B, Shibamoto Y, Acimovic L and Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14: 1065–1070
Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A and Milisavljevic S (1998) Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42: 1091–1096
Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, Vinciguerra V, Rosenbluth R, Bosselli R, Cochran C and Sheehan K (1990) Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8: 313–318
Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL and Livingston RB (1998) Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16: 3078–3081
Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier M, Douillard J and Laplanche A (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417–423
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW and Curran WJ (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91–96. J Clin Oncol 14: 1055–1064
Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D and Frei E (1994) Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer 73: 1171–1176
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225S–233S
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br Med J 311: 899–909
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Custem O, Sergysels R, Mommen P and Klastersky J (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13: 1221–1230
Roach M, Gandara DR, Yuo H, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L and Phillips TL (1995) Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13: 2606–2612
Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J and Al-Sarraf H (1985) Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55: 1123–1128
Saunders MI, Dische S, Barrett A, Parmar MKB, Harvey A and Gibson D (1996) Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim analysis. Br J Cancer 73: 1455–1462
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, Dar AR and Cox JD (1995) Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87: 198–205
Scanlon KJ, Newman EM, Lu Y and Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923–8925
Segawa Y, Takigawa N, Kataoka M, Takata I, Fujimoto N and Ueoka H (1997) Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 39: 91–98
Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RB, Choi NC, Rege VB, Modeas C and Green MR (1992) Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10: 1237–1244
Tsuchiya S, Minato K, Nakano H, Takise A, Ezawa K, Fueki N, Hoshino H, Naruse I, Takei Y, Makimoto T, Nomoto T, Ishihara S, Mori M and Saito R (1995) A phase II study of 72-hour continuous infusion consisting of cisplatin and 5-fluorouracil for treatment of non-small cell lung cancer. Oncology 52: 246–250
Vokes EE and Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911–934
Weiden PL and Piantadosi S (1991) Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 83: 266–272
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Segawa, Y., Ueoka, H., Kiura, K. et al. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 82, 104–111 (2000). https://doi.org/10.1054/bjoc.1999.0885
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0885
Keywords
This article is cited by
-
Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology (2018)
-
Concurrent chemoradiotherapy using cisplatin plus s-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: A single-center feasibility study
Surgery Today (2011)
-
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
British Journal of Cancer (2006)
-
The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology (2006)
-
Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter
Journal of Cancer Research and Clinical Oncology (2005)